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Malaria chemoprophylaxis: strategies for risk groups
Abstract
The risk of malaria for travelers varies from region to region and depends on the intensity of
transmission, the duration of the stay in the area of endemicity, the style of travel, and the efficacy of
preventive measures. The decision to recommend chemoprophylaxis to travelers to areas with a low risk
of malarial infection is especially difficult because the risk of infection must be balanced with the risk of
experiencing side effects. If the risk of side effects by far exceeds the risk of infection, the traveler needs
information on measures against mosquito bites and advice on prompt diagnosis and self-treatment. The
risk is difficult to quantify, and the absolute risk for travelers to most areas is not known, especially
because the populations at risk are unknown. We propose here that the best approximation of the risk to
the traveler to a specific area is to use the risk to the indigenous population as a guideline for the risk to
the traveler, and we provide examples on how risk in the indigenous population can be used for the
estimation of risk of malarial infection for travelers. Special groups are long-term visitors and residents,
who often perceive risk differently, cease using chemoprophylaxis, and rely on self-diagnosis and
treatment. For long-term visitors, the problem of fake drugs needs to be discussed. Strategies for
chemoprophylaxis and self-treatment of pregnant women and small children are discussed. So far,
malaria prophylaxis is recommended to prevent Plasmodium falciparum infections, and primaquine
prophylaxis against persistent Plasmodium vivax and Plasmodium ovale infections in travelers is not
recommended.
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INTRODUCTION
The prevention of malaria in nonimmune persons visiting
areas where malaria is endemic is difficult due to a lack of data
on the risk of infection for the traveler, disagreement between
professionals and national guidelines on optimum strategies,
and the risk of side effects from prophylaxis.
An estimated 80 to 90 million travelers visit areas where
malaria is endemic annually. Not all travelers have a similar
risk. The risk of acquiring malaria depends on many factors
including the type and intensity of malaria transmission at the
destination, the duration and style of travel, the prevention
measures used, and individual characteristics (3, 7, 28). Ma-
laria prevention advice should be evidence based, using sound
epidemiological data when available. Travelers to areas where
malaria is endemic need (i) information on the disease, its
mode of transmission, incubation period, and symptoms; (ii)
advice on measures against mosquito bites; (iii) chemoprophy-
laxis for high-risk areas such as sub-Saharan Africa; and (iv)
advice regarding prompt diagnosis and self-treatment of ma-
laria if appropriate.
The decision to use chemoprophylaxis depends on a risk-
benefit analysis weighing the risk of malaria against the risk of
possible adverse drug reactions. The risk of infection for trav-
elers is difficult to quantify, and new at-risk areas may emerge
(16). Even though malaria imported to countries where ma-
laria is not endemic is a notifiable disease, the population at
risk, i.e., the exact number of travelers to a specific destination,
is often impossible to ascertain. It can be useful, therefore, to
use data on malaria endemicity in the indigenous population
and then extrapolate the risk to travelers (31). Several studies
quantified the rate of adverse events in short-term travelers
using malaria chemoprophylaxis, but the methodologies used
are rarely comparable so that incidence rates among studies
can differ enormously. Data on the long-term use and tolera-
bility of drugs for chemoprophylaxis are lacking. There is also
a lack of data on the safety and efficacy of strategies for other
at-risk groups such as pregnant/lactating women and small
children.
In this paper, we attempt to identify traveler types who are
particularly at risk of malaria and to suggest evidence-based
strategies for the various risk groups.
RISK OF MALARIAL INFECTION
One of the most difficult questions in malaria prophylaxis
today is how to advise travelers who visit low-risk areas, which
are often areas with unstable transmission and a changing
malaria epidemiology. Few studies reported the absolute risk
in specific areas, but these data are necessary to allow a ratio-
nal decision on whether to recommend chemoprophylaxis or
not balanced against the risk of side effects. Travelers should
not be exposed to a substantial risk of adverse events from
malaria chemoprophylaxis in areas where the risk of malarial
infection is very low.
Can we quantify the risk of contracting malaria and weigh
this against the risk of adverse events from chemoprophylaxis?
A recent study from Sweden found the risk of malaria to trav-
elers to be 302 per 100,000 visitors to western Africa, 46 per
100,000 visitors to South Africa, 7.2 per 100,000 visitors to South
America, and 2 per 100,000 visitors to Thailand (2). Studies from
travelers returning to the United Kingdom two decades ago
found that 1 in 77 or 1,300 per 100,000 persons visiting friends and
relatives in Ghana contracted malaria, falling to 1 per 100,000
travelers to South America (25). A study of malaria in travelers
returning to Denmark found that 158 per 100,000 travelers visit-
ing The Gambia, 76 per 100,000 travelers visiting Indonesia, and
1.7 per 100,000 travelers visiting Thailand contracted malaria
(17). A declining risk of malaria in travelers to South America has
also been reported (4).
Table 1 shows the risk of malaria for short-term travelers at
different levels of endemicity in the indigenous population and
the rate of mortality for travelers, assuming a case fatality rate of
2%. The relationship between endemicity measured by the an-
nual parasite rate in the indigenous population and the estimated
* Corresponding author. Mailing address: Department of Infectious
Diseases, Aarhus University Hospital—Skejby, Aarhus, Denmark.
Phone: 45 8949 8307. Fax: 45 8949 8360. E-mail: epf@sks.aaa.dk.
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attack rates in nonimmune travelers is shown in Fig. 1. We as-
sume that the risk of malaria in travelers and that in the indige-
nous population are the same, which may not always be true. The
risk in the indigenous population should therefore be seen as a
maximal-risk situation, with a lower risk for travelers staying in
houses with air conditioning. An endemicity level of 20 cases per
1,000 indigenous people would result in an estimated 1 death per
100,000 travelers per year without chemoprophylaxis. This would
increase to 8 deaths per 100,000 travelers at an endemicity level of
100 cases per 1,000 indigenous persons. It should be noted that
the rate of 8 deaths per 100,000 persons per year is very close to
the annual risk of being killed in traffic in Europe, which is ap-
proximately 1 death per 11,500 inhabitants per year (http://epp
.eurostat.ec.europa.eu/).
RISK OF ADVERSE EVENTS FROM
MALARIA CHEMOPROPHYLAXIS
The risk of being infected with malaria should be balanced
with the risk of adverse events from malaria chemoprophylaxis.
Adverse events can be divided into common events, usually
mild and affecting high percentages of users, and rare events,
which are seen much less frequently and which are often rec-
ognized only after millions of patients have used the drug.
Rare events are usually not discovered in phase III trials prior
to licensing of a drug and rely on postmarketing surveillance
after licensing, which makes the true incidence very uncertain,
as unreported events are likely.
There is only one double-blind, randomized controlled trial
that compared all current malaria-prophylactic regimens and
associated adverse events in 623 travelers randomized to
atovaquone-proguanil (Malarone), mefloquine (Mephaquin
or Lariam), doxycycline, and chloroquine plus proguanil (as
Savarine) (30). Forty-five percent of chloroquine and proguanil
users, 42% of mefloquine users, 33% of doxycycline users, and
32% of atovaquone-proguanil users reported mild to moderate
adverse events. Severe adverse events (that interfered with
daily activity) were reported for 11% of mefloquine users, 12%
of chloroquine plus proguanil users, 6% of doxycycline users,
and 7% of atovaquone and proguanil users. It should be em-
phasized that an adverse event is not necessarily attributable to
the antimalarial drug but reflects all intercurrent events expe-
rienced during the use of the drug. A recent detailed review (9)
showed that despite widespread reports on the adverse effects
FIG. 1. Spatial relationship between annual parasite rates in the indigenous population and estimated attack rates in nonimmune travelers
visiting the same area. It is assumed that the annual parasite rate reflects the risk of malaria infection and that each individual is infected only once
during the 12-month period, and it is assumed that an infection in a nonimmune traveler is always symptomatic.
TABLE 1. Risk of malaria in short-term travelers at different levels of endemicity in the indigenous population and mortality
from malaria in short-term travelersa
Annual incidence of
malaria cases in
local population
Example of area of endemicityb
Incidence per
wk per 100,000
travelers
Incidence per 2
wk per 100,000
travelers
without
prophylaxis
Incidence per 2 wk per
100,000 travelers with
prophylaxis assuming
90% efficacy of
prophylaxis
Mortality per
100,000
travelers per
2 wk without
prophylaxis
Mortality per
100,000
travelers per
2 wk with
prophylaxis
1 per 1,000 Mexico, parts of South America,
Vietnam (except Binh Province)
1.9 3.8 0.4
10 per 1,000 Parts of Vietnam (Binh
Phuoc province)
19.2 38.5 3.8
20 per 1,000 Parts of India (Assam, Gujarat,
Orissa, Rajastan)
38.4 76.8 7.7 1
50 per 1,000 Parts of South Africa 96.1 192.3 19.2 4
100 per 1,000 Western Africa 192.3 384.6 38.5 8 0.5
a Assuming a case fatality rate of 2%. Short-term travel is considered to be travel in a region of endemicity lasting 2 weeks or less.
b The areas mentioned serve only as examples of areas with different levels of endemicity in the indigenous population. Risk in southeastern Asia is very unevenly
distributed within each country and should be assessed at district levels based on the travelers’ planned route and using malaria maps (30).
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of mefloquine, controlled studies (involving 5,000 subjects)
found a low incidence of serious adverse events. Studies of
minor adverse events have, however, highlighted the neuropsy-
chiatric/neuropsychological profile of this antimalarial drug,
showing an excess of such events in women.
PROPHYLAXIS FOR SHORT-TERM VISITORS
We will not discuss the proper selection of drugs or dosage
for chemoprophylaxis for a given area here, as this information
was reported elsewhere (6, 31, 40).
Short-term travelers are persons visiting an area where ma-
laria is endemic for weeks or a few months. This group includes
most tourists, and the main reason for travel is business and
leisure. The travelers usually have little prior knowledge of
disease, including malaria risk at their destination. Because of
the incubation period of malaria, many short-term travelers
who acquire the disease will be diagnosed after return. The
actual profile of imported species varies among countries, re-
flecting the primarily geographic origin of the infection. Ma-
laria deaths are due almost exclusively to infection with Plas-
modium falciparum (1).
At present, the key problem for travel health practitioners is
when to advise the use of chemoprophylaxis for travelers to
low-risk areas of endemicity. Based on the estimates of risk for
malaria and adverse events, we propose that the prescription of
chemoprophylaxis in areas with an endemicity level in the
indigenous population below 10 cases per 1,000 population per
year is not justified (Table 1). To prevent one case at this level
of transmission, 2,600 travelers should be prescribed chemo-
prophylaxis, and to prevent one fatality, assuming a 2% case
fatality rate, 130,000 travelers should be prescribed chemopro-
phylaxis (Table 2). For comparison, the proper use of impreg-
nated bed nets can reduce the risk of infection by 50% without
causing adverse events in users (1). However, it should be
noted that clinical malaria cases in the local population may
reflect a lower attack rate than that for visitors if there is
substantial clinical immunity in the local population. There-
fore, the level of endemicity should be determined by the
parasite rate and not the rate of reported clinical malaria cases
in the indigenous population.
Standby emergency treatment (SBET), where the traveler is
prepared to self-treat a suspected case of malaria if he or she
has symptoms suggestive of malaria and is out of reach of
medical attention, is recommended by many authorities as a
strategy for short-term travelers to low-risk destinations (6, 24,
40). However, SBET is not indicated for travelers on trips
shorter than the incubation period for malaria, which is a
minimum of 6 days for P. falciparum malaria.
PROPHYLAXIS FOR LONG-TERM VISITORS AND
FREQUENT VISITORS
The risk of malaria cumulates over time, but the increased
risk cannot be attributed to longer exposure alone (25). Long-
term travelers, defined as persons staying permanently in an
area for 6 months or longer, and frequent travelers to regions
of endemicity behave differently from short-term visitors.
Long-term travelers frequently discontinue chemoprophylaxis
prematurely because they perceive the risk to be lower than
expected. They also believe that they can effectively manage an
infection, and they worry about side effects from the long-term
use of malaria chemoprophylaxis (8, 37). The use of counter-
feit drugs (fake drugs containing no or subtherapeutic doses of
active compounds) is particularly an issue for long-term trav-
elers, who often buy supplies of dubious quality, and expatri-
ates should be encouraged to bring adequate quantities of
antimalarial medications with them (37). The consequences for
travelers using counterfeit drugs are far-reaching: high levels of
mortality due to untreated P. falciparum infection, subthera-
peutic dosages leading to inadequate prophylactic doses, a risk
of increased adverse events due to excessive dosage or poten-
tially toxic contaminants, and, finally, a loss of faith in genuine
medicines.
The health personnel advising long-term travelers should
understand these aspects and accept that these are important
issues that must be addressed.
The key to managing malaria prevention in long-term and
frequent travelers is to provide the travelers with a knowledge
and understanding of malaria so that they can take more re-
sponsibility for their own health compared to the short-term
traveler.
Long-term travelers to high-risk areas should take malaria che-
moprophylaxis, even if this is necessary over several years. Me-
floquine is the best-documented drug for long-term travelers and,
if well tolerated, can be used for prolonged periods; i.e., there is
no upper time limits for the use of mefloquine (34). It has a
simple weekly dosing schedule that encourages adherence (39),
and toxic accumulation in the body does not occur during long-
term use (14). Doxycycline (a tetracycline compound) is used for
TABLE 2. Numbers of travelers needed to take chemoprophylaxis to prevent one case of malaria and to prevent one fatal case of malaria at
different levels of endemicity
Annual incidence of cases
of malaria in local
population
No. of travelers needed
Taking prophylaxis to
prevent 1 casea
Taking prophylaxis to
prevent 1 deatha,b
With severe side effects to
prevent 1 malaria casec
With severe side effects to
prevent 1 deathc
1 per 1,000 26,000 1,300,000 2,600 130,000
10 per 1,000 2,600 130,000 260 13,000
20 per 1,000 1,300 65,000 130 6,500
50 per 1,000 520 26,000 52 2,600
100 per 1,000 260 13,000 26 1,300
a Assuming 2 weeks of travel.
b Assuming 2% mortality.
c Severe side effects in 10% of cases.
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the treatment of skin infections for months, but side effects, es-
pecially vaginal candidiasis in women, is a problem for long-term
users. A third option is the use of atovaquone-proguanil (13). The
CDC has no upper limit on the duration of intake of atovaquone-
proguanil (6), and recent United Kingdom guidelines consider
atovaquone-proguanil to be safe for continuous use of up to 12
months (36).
This means that long-term travelers must have knowledge
about malaria as a disease, including key symptoms such as
fever, the adequate use of SBET, the problems of counterfeit
drugs, and the need to identify reliable health care facilities in
case of emergency.
Mosquito bite prophylaxis is even more relevant for the
long-term traveler, and comprehensive information about
screening, impregnated bed nets, coils, repellents, insecticides,
and the biting habits of mosquitoes is required. The systemic
use of impregnated bed nets can reduce the risk of malaria by
50% (19). In selected cases, the long-term traveler may be
trained to use rapid malaria diagnostic kits, but this option
needs to be restricted to persons staying in isolated places, and
thorough pretravel instruction is essential (31).
Health personnel advising travelers must recognize that this
group is unlikely to take chemoprophylaxis continuously for
years, and it will increase our credibility if travel health advi-
sors acknowledge this and try to realistically prepare this group
for their long-term travel.
Suggestions for advice to long-term travelers and frequent vis-
itors are as follows: (i) inform travelers about disease, symptoms,
diagnosis, and need for rapid treatment; (ii) discuss access to
qualified medical assistance at destination and the need to iden-
tify qualified medical staff before the traveler becomes ill; (iii)
inform travelers about alternatives to continuous chemoprophy-
laxis; (iv) provide detailed advice on methods to prevent mosquito
bites; (v) inform travelers about the use of SBET and emphasize
the need for medical assessment despite the use of SBET; and (vi)
inform travelers about the problems with counterfeit drugs in
many countries where malaria is endemic and that drugs for both
chemoprophylaxis and SBET should be purchased before arriving
at the destination. Rapid diagnostic tests can be recommended
for selected travelers but require comprehensive pretravel in-
struction. The drug of choice for SBET depends on the use of
prophylaxis, if any, the expected drug susceptibility pattern at the
destination, and the guidelines of the traveler’s country of origin,
and as a rule, the drug used for treatment should not be the same
as that used for prophylaxis. Malaria breakthrough while compli-
ant and on prophylaxis could be due to resistance of the P. fal-
ciparum parasite to the chemoprophylactic drug, which is why the
drug used for prophylaxis should not be reused for treatment.
PROPHYLAXIS AGAINST PLASMODIUM VIVAX AND
PLASMODIUM OVALE
The main goal of malaria chemoprophylaxis is to prevent P.
falciparum infection, which is primarily responsible for malaria
fatalities. However, both Plasmodium vivax and Plasmodium
ovale can cause serious febrile illness in nonimmune patients.
The clinical presentation of P. vivax and P. ovale malaria can-
not be distinguished from that of P. falciparum malaria (5).
The burden of infection is considerable in indigenous popula-
tions, and P. vivax is the most prevalent malaria type in south-
east Asia and South America and is found in eastern Africa (21).
P. vivax is susceptible to most antimalarial drugs, although isolates
with reduced sensitivity to chloroquine and primaquine have been
found in parts of Indonesia and in Papua New Guinea, Iraq, and
Afghanistan (3, 33, 35). There is a decreased susceptibility of P.
vivax to sulfadoxine-pyrimethamine in Thailand (26).
A study from Europe of 518 imported cases of P. vivax found
that 60% of patients were admitted to the hospital on average
4 days after the start of symptoms, and seven patients had
severe complications (hepatosplenomegaly [three patients],
spleen rupture [one patient], pancytopenia [one patient], mac-
rohematuria [one patient], and psychosis [one patient]) (23).
P. vivax and P. ovale develop hypnozoites when the host is
infected, which may relapse later and cause malaria symptoms
long after the traveler has returned home. Hypnozoites are
susceptible only to primaquine. One study found that the first
P. vivax attack was seen approximately 3 months after leaving
the area where malaria is endemic regardless of whether the
traveler had taken prophylaxis or not (12). The prevention of
relapsing P. vivax infection can be achieved only by presump-
tive posttravel treatment with a course of primaquine or by
using primaquine as a chemoprophylaxis during travel. So far,
neither of these options has been extensively used, and prima-
quine is not registered as primary prophylaxis in most coun-
tries. Terminating a stay in an area where P. vivax is endemic
with a 2-week course of primaquine without knowing whether
the traveler is infected or not is not attractive for practitioners
and patients, as primaquine has some side effects, causing
primarily methemoglobinemia. The use of primaquine requires
that the individuals be tested for glucose-6-phosphate defi-
ciency (G6PD). The recommended adult dose for “antirelapse
treatment” based on clinical trials and expert opinion is 30 mg
base daily for 14 days, starting upon return from a region
where malaria is endemic and taken together with a blood
schizonticide based on evidence from the 1950s showing that
primaquine’s activity against hypnozoites is enhanced when
given with chloroquine. The adult dose for primary prophylaxis
is 30 mg daily starting 1 day before travel and continuing for 7
days after return (15).
One study used primaquine as prophylaxis alone in an area
with a high risk of P. falciparum infections and found break-
throughs in four users (32). Primaquine has only limited activ-
ity against P. falciparum blood-stage activity, and if parasites
emerge from the liver into the blood, primaquine alone will be
insufficient as chemoprophylaxis.
The use of primaquine as the drug of choice for travelers to
areas where P. vivax is endemic raises the concern of inducing
primaquine resistance, which so far has been found only in
Irian Jaya, Papua New Guinea, along with a single report from
Iraq and Afghanistan (35).
As long as the absolute risk of infection by P. vivax and P.
ovale is not known, the best strategy is still to inform travelers
of the risk of a late-onset attack of P. vivax or P. ovale after
return and cessation of chemoprophylaxis.
MALARIA PREVENTION FOR PREGNANT AND
BREASTFEEDING WOMEN
A significant proportion of travelers are women with child-
bearing potential who need evidence-based advice on the use
VOL. 21, 2008 MALARIA CHEMOPROPHYLAXIS 469
 at UNIVERSITATSSPITAL on February 23, 2009 
cm
r.a
sm
.o
rg
D
ow
nloaded from
 
of antimalarials in the periconception period, during preg-
nancy, and when breastfeeding. Malaria during pregnancy is
hazardous for the mother, the fetus, and the neonate and is an
important cause of maternal and child morbidity and mortality
(11). Plasmodium falciparum is responsible for the main bur-
den of malarial disease in pregnant women (20). Other malaria
species do not parasitize placental blood to the same extent
and hence have less impact (11). The clinical features of P.
falciparum malaria in pregnancy depend to a large extent on
the immune status of the woman, which in turn is determined
by her prior exposure to malaria. Nonimmune travelers have
little or no immunity and are prone to episodes of severe
malaria, leading to stillbirths, spontaneous abortions, or even
maternal death. Mosquito bite protection is essential, and re-
search shows that N,N-diethyl-3-methylbenzamide is effective
and safe and has a low risk of accumulation in the fetus (20).
Pyrethroid insecticide-treated nets are safe and have been
shown to substantially reduce the risk of placental malaria (18,
22). Bed nets are particularly indicated in rooms with no air
conditioning.
Malaria chemoprophylaxis in pregnancy is complex. Due to
ethical and safety restrictions, few antimalarial drugs have
been evaluated for pregnant travelers, and there is also a
dearth of information on drug disposition in pregnant woman
(Table 3). Chloroquine can be used, but widespread resistance
limits this option. Doxycycline and primaquine are contraindi-
cated. Due to insufficient data, atovaquone-proguanil is not
recommended, although proguanil is considered to be safe
during pregnancy, and no teratogenicity has been observed in
animal studies using atovaquone. Mefloquine is an option for
pregnant women who cannot defer travel and who need che-
moprophylaxis for areas where chloroquine-resistant malaria is
endemic. Some authorities now allow the use of mefloquine in
all trimesters, and others advise against using the drug in the
first trimester apart from exceptional circumstances. A recent
trial of chloroquine prophylaxis for P. vivax malaria in pregnant
women in Thailand found no effect on maternal anemia or
birth weight (38). However, in areas with predominantly P.
vivax malaria, infection in pregnancy contributes to maternal
morbidity and mortality (27).
With regard to breastfeeding, chloroquine, hydroxychloro-
quine, and mefloquine are considered to be compatible with
breastfeeding, and atovaquone-proguanil can be used if the
breastfed infant weighs more than 5 kg. Proguanil is excreted
into human milk in small quantities, and in a rat study, atova-
quone concentrations in milk were 30% of the concurrent
atovaquone concentrations in maternal plasma. Infants who
are breastfed do not receive adequate concentrations of any
antimalarial drugs and require their own chemoprophylaxis
(29).
MALARIA PREVENTION FOR SMALL CHILDREN
Imported malaria case numbers in children are increasing
with the rise in travel among children and changing profiles of
immigrants, particularly settled immigrants visiting friends and
relatives in countries where malaria is endemic. The use of
N,N-diethyl-3-methylbenzamide containing insect repellents is
recommended for children older than 2 months of age, and an
alternative repellent, picaridin, can be recommended for chil-
dren older than 2 years of age. Chloroquine is safe for children
of all ages and weights, but the use of this option is delimited
TABLE 3. Antimalarials for chemoprophylaxis and SBET in pregnancy
Antimalarial Recommendation for chemoprophylaxisin pregnancy
Recommendation for emergency self-
treatment in pregnancy Description
Atovaquone-proguanil No data; should not be used No data; should be used only if no
other options are available
Not recommended due to lack of
safety data; inadvertent use in
pregnancy probably safe, but
few data are available
Chloroquine
(hydroxychloroquine)
Can be used Can be used Regarded as safe
Proguanil Can be used Not used for treatment Supplement with folic acid is
recommended
Doxycycline Contraindicated Contraindicated May cause bone malformation
and discolored teeth
Mefloquine Can be used after the first trimester;
some authorities (WHO and
CDC) allow the use of mefloquine
in the first trimester if the risk of
malaria is high and travel cannot
be deferred
Can be used after 16th gestational
wk or if no other options are
available
Regarded as safe after 16th
gestational wk based on
postmarketing surveillance;
inadvertent use periconception
or during pregnancy is not
considered an indication for
termination
Artemisinins Not used for prophylaxis Few data; can be used only if no
other options are available
One small study found no
adverse impact on the
pregnant mother or the fetusa
Quinine Not used for prophylaxis Can be used Drug of choice for P. falciparum
malaria; combination with
clindamycin is recommended
Primaquine Contraindicated Treatment of P. vivax hypnozoites
should be deferred until after
pregnancy
Use of primaquine in pregnancy
would necessitate G6PD
testing for mother and fetus
a See reference 10.
470 SCHLAGENHAUF AND PETERSEN CLIN. MICROBIOL. REV.
 at UNIVERSITATSSPITAL on February 23, 2009 
cm
r.a
sm
.o
rg
D
ow
nloaded from
 
by widespread resistance to the drug. Mefloquine can be used
for children 5 kg and atovaquone-proguanil prophylaxis (as
pediatric tablets) can be used for children 5 kg according to
new CDC guidelines (6). The manufacturer, the World Health
Organization (40), and some European authorities sanction
the use of this combination only for children weighing more
that 11 kg. Artemether-lumefantrine (Coartem), an artemisi-
nin combination in dispersible tablet form with cherry flavor,
will be available in 2008 for the treatment of infants (Novartis,
Switzerland) but cannot be used for prophylaxis. Doxycycline is
indicated for children aged 8 years (and allowed for children
over 12 years of age in the United Kingdom). Table 4 shows
the currently recommended doses for malaria prophylaxis in
children.
When possible, deferral of travel is recommended for preg-
nant and breastfeeding women and also for young children.
CONCLUSIONS
The risk of malarial infection can be based to some extent on
the annual incidence data in the indigenous population. The
risk of malaria infection should be balanced with the risk of
TABLE 4. Antimalarial chemoprophylaxis for children
Antimalarial Indication for chemoprophylaxis Dosing Description
Atovaquone-proguanil 5 kg body wt per CDCa Daily Palatable
11 kg body wt per manufacturer
and some European countries
Pediatric tablets Expensive
Chloroquine (hydroxychloroquine) All ages and weights 5 mg base/kg
weekly
Limited use due to resistance
Proguanil All ages and weights 3 mg/kg/day Only in combination with chloroquine
Doxycycline Children 8 yr old 1.5 mg salt/kg daily Contraindicated for small children
Mefloquine Children 5 kg 5 mg/kg weekly Bitter taste
Primaquine Children 4 yr old per WHO 0.5 mg/kg base G6PD testing essential
CDC specifies no lower age limit Daily Last choice
a New recommendations for 2007.
TABLE 5. Examples of travel itineraries, risk estimation, and suggested advice for adults and nonpregnant travelers
Country Travel itinerary Risk estimation Recommendation
Vietnam 3 wk traveling from Hanoi to Ho Chi Minh
City primarily along the coast
Very limited; the only area of Vietnam
where the annual parasite rate
exceeds 10 per 1,000 individuals per
yr is in the central highlands
bordering Laos
No chemoprophylaxis; use
impregnated bed nets
and repellants; carry
SBET
South Africa 3 days in Kruger National Park and 2 wk
traveling in the rest of the country down
to Cape Town
Risk in Kruger National Park but not
the remaining part of the visit;
chloroquine resistance reported
Chemoprophylaxis
recommended in
Kruger National Park,
and doxycycline,
mefloquine, or
atovaquone-proguanil
(most practical option
for short-term use) can
be used
Mexico Visiting Yucatan including Palenque and
San Cristobal de la Casas for 2 wk
Low-risk area No chemoprophylaxis; use
impregnated bed nets
and repellants
Tanzania Pregnant student who planned a 3-mo stay
in rural Tanzania found out she was
pregnant gestational wk 12 6 wk before
leaving
High-risk area; chemoprophylaxis
highly needed; chloroquine
resistance widespread
Doxycycline is
contraindicated in
pregnancy, and data are
lacking on the safety of
atovaquone-proguanil;
mefloquine is
considered safe after
gestational wk 16
Ghana 12-wk-old infant; Ghanean family living in
Europe had their first child 3 mo ago
and want to visit their family in Ghana
living in the rural areas north of Kumasi
High-risk area; recommend deferral of
travel; chemoprophylaxis and
mosquito bite protection essential
Doxycycline
contraindicated;
mefloquine possible for
infants weighing 5 kg;
tablets can be cut and
crushed; atovaquone-
proguanil is
recommended by some
authorities for children
5 kg
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severe and serious adverse events from the use of chemopro-
phylaxis (Table 5). We propose that travelers to areas with an
annual incidence of malaria in the indigenous population of
below 10 cases per 1,000 individuals should not be advised to
use chemoprophylaxis but should rely on preventing mosquito
bites alone and on the carriage of standby emergency self-
treatment. Travelers need to be aware of the risks and time
frames of late-onset malaria, particularly P. vivax malaria.
Pregnant or breastfeeding mothers and travelers with small
children require expert advice on malaria prevention and
choice of drug and should defer travel to high-risk areas. Long-
term travelers must take more responsibility and receive com-
prehensive advice on all aspects of malaria prevention and
treatment. This group needs thorough pretravel advice with
particular emphasis on the prevention of mosquito bites, sea-
sonal prophylaxis, if appropriate, the use of and potential risks
from long-term use of chemoprophylaxis, advice on SBET, and
the possible use of rapid diagnostic tests. Recommendations
on antimalaria strategies and choice of drug differ among
countries because precise and up-to-date data are lacking for
many areas and because there is a lack of international con-
sensus.
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